Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
Stopped The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.
Conditions
- Pancreatic Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
Interventions
- BIOLOGICAL: Pembrolizumab
- BIOLOGICAL: Wild-type Reovirus
Sponsor
Northwestern University
Collaborators